Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases

Phase 1 Recruiting 7 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a phase Ib/III, randomized, multicenter study evaluating the efficacy and safety of hepatic arterial infusion of paclitaxel cationic liposome in combination with systemic therapy (Oxaliplatin, Capecitabine, with or without Bevacizumab) as first-line treatment in colorectal liver metastases.

Timeline

Start: 2025-05-13
Primary completion: 2025-12-30
Completion: 2026-06-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Paclitaxel	Small molecule	33 mg/m2	Other
Subject	Paclitaxel	Small molecule	55 mg/m2	Other
Background	Bevacizumab	Monoclonal antibody	7.5 mg/kg	Intravenous
Background	Capecitabine	Small molecule	1000 mg/m2	Oral
Background	Oxaliplatin	Small molecule	130 mg/m2	Intravenous

Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases

Summary

Timeline

Drugs

Indications